Calliditas Therapeutics AB (CALT)

NASDAQ: CALT · IEX Real-Time Price · USD
19.45
0.99 (5.36%)
At close: May 20, 2022 4:00 PM
18.70
-0.75 (-3.86%)
After-hours:May 20, 2022 5:05 PM EDT

Income Statement (Quarterly)

Millions SEK. Fiscal year is Jan - Dec.
Quarter Ended2021-12-312021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-30
Revenue
-000.4000.4746.590138.24
Revenue Growth (YoY)
----99.14%------
Gross Profit
-000.4000.4746.590138.24
Selling, General & Admin
-84.3758.7863.8841.0418.818.0123.7910.319
Research & Development
-75.0290.0873.9964.8948.3954.1141.7146.1931.19
Other Operating Expenses
00.011.93-1.53-1.03-0.620.69-0.87-3.842.67
Operating Expenses
-159.4150.78136.34104.8966.5672.864.6352.6452.86
Operating Income
--159.4-150.78-135.94-104.89-66.56-72.33-18.04-52.6485.39
Interest Expense / Income
-5.81-14.6137.8833.05-5.3-8.655.86-2.52.22
Other Expense / Income
0-3.23-1.41-3.56000-0.9300
Pretax Income
0-161.98-134.76-170.26-137.94-61.26-63.68-22.97-50.1483.17
Income Tax
--2.14-9.310.180.080.070.040.0800
Net Income
--159.84-125.46-170.43-138.02-61.33-63.72-23.05-50.1483.17
Net Income Common
--159.84-125.46-170.43-138.02-61.33-63.72-23.05-50.1483.17
Shares Outstanding (Basic)
5050504646464646--
EPS (Basic)
--6.40-5.02-7.48-5.54-3.00-3.30-1.46-2.604.72
EPS (Diluted)
--6.40-5.02-7.48-5.54-3.00-3.30-1.46-2.604.70
Free Cash Flow Per Share
--5.32-5.37-5.19-4.46-2.90-0.81-1.97--
Gross Margin
---100.00%--100.00%100.00%-100.00%
Operating Margin
----33985.25%---15258.65%-38.73%-61.77%
Profit Margin
----42607.75%---13441.98%-49.48%-60.16%
Free Cash Flow Margin
----30018.50%---3960.97%-97.78%--42.90%
Effective Tax Rate
-1.32%6.90%-0.10%-0.06%-0.11%-0.06%-0.34%0.00%0.00%
EBITDA
--156.17-149.37-132.38-104.89-66.56-72.33-17.12-52.6485.39
EBITDA Margin
----33094.25%---15258.65%-36.74%-61.77%
EBIT
--156.17-149.37-132.38-104.89-66.56-72.33-17.12-52.6485.39
EBIT Margin
----33094.25%---15258.65%-36.74%-61.77%
Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).